Clinical Development & Evidence Strategy
Focus Areas
- •Clinical protocol design focused on risk-contextualisation
- •Evidence-based strategy for regulatory and board discussions
- •Synthesis of clinical, mechanistic, and epidemiological data
Designing Evidence for Decision Context
This pillar should be seen as a continuation of Pillar 1, translating early safety hypotheses and uncertainty mapping into concrete clinical evidence strategies and protocol design choices.
Clinical development is often approached as an execution challenge, yet many of the most consequential risks are design risks.
A flawlessly executed study that answers the wrong question remains a wasted asset.
I focus on protocol risk framing and evidence strategy, helping teams move beyond "can we run this study?" to the more important question: "Will this study meaningfully support the decision we need to make?"
This approach ensures that clinical evidence is designed with decision context in mind — not retrospectively interpreted after uncertainty has already crystallised.
Protocol Risk Framing
Evaluation of trade-offs between speed, feasibility, and evidentiary robustness — with early identification of safety, interpretative, and decision risks before protocols are finalised.
Epidemiology & RWE
Strategic use of epidemiology and real-world evidence to contextualise emerging safety signals, using background rates and external data to distinguish true risk from noise.
Regulatory-Aligned Strategy
Framing safety and benefit–risk arguments in regulator-relevant language, with strategic preparation for Scientific Advice, Health Authority interactions, and Board-level discussions.
Portfolio & Program-Level Strategy
For organisations managing multiple programs, I provide comparative assessments of evidence strength and uncertainty. This enables data-driven prioritisation and capital allocation.
Discuss Portfolio Strategy